Helsinn
Helsinn and MEI Pharma join forces to develop leukaemia drug Pracinostat
August 9, 2016Manufacturing and Production, Research and Development Helsinn, MEI Pharma, Pracinostat, chronic myeloid leukaemia
Swiss pharmaceutical group Helsinn has entered an agreement with MEI Pharma over the licensing, development and commercialisation of Pracinostat (SB939) …
FDA approves Eisai’s chemo side-effects drug
October 15, 2014Research and Development, Sales and Marketing Eisai, FDA, Helsinn, akynzeo, chemotherapy, cinv
Eisai and Helsinn Healthcare’s Akynzeo (netupitant/palonosetron) has received FDA approval for the treatment of chemotherapy-induced nausea and vomiting (CINV). CINV …
Helsinn expands high-potency plant with cytotoxics suite
March 8, 2011Manufacturing and Production APIs, CMOs, GMP, Helsinn, Helsinn Advanced Synthesis, Swiss pharma contract manufacturing, contract manufacturing, high-potency APIs
Helsinn is on track to complete construction of a new manufacturing plant for cytotoxic active pharmaceutical ingredients in Biasca, Switzerland, …
Helsinn restructures API units in Switzerland, Ireland
June 23, 2009Manufacturing and Production Helsinn
Pharmaceutical group Helsinn is planning to expand its manufacturing capabilities with a new round of investment at a production facility …
Helsinn chooses Dublin for R&D investment
April 14, 2009Research and Development Helsinn
Helsinn Birex Pharmaceuticals is to invest 13 million euros in a new pilot-scale R&D facility in Ireland, to help it …
